Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).
about
IQGAP1 protein binds human epidermal growth factor receptor 2 (HER2) and modulates trastuzumab resistanceCixutumumabTargeting the insulin growth factor receptor 1LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergyTrastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancerImmunohistochemical expression of insulin-like growth factor binding protein-3 in invasive breast cancers and ductal carcinoma in situ: implications for clinicopathology and patient outcome.Cytoplasmic p21WAF1/CIP1 expression is correlated with HER-2/ neu in breast cancer and is an independent predictor of prognosisThe future of cytotoxic therapy: selective cytotoxicity based on biology is the keyInhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cellsMechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancerHuman epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic optionsTargeting of erbB3 receptor to overcome resistance in cancer treatmentResistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategiesThe insulin-like growth factor system in cancerHuman epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancerMonoclonal antibodies for the treatment of cancerSignaling cross-talk in the resistance to HER family receptor targeted therapyAutophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumabSmall-molecule inhibition and activation-loop trans-phosphorylation of the IGF1 receptorPTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancerDissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast CancerPotentiating the efficacy of molecular targeted therapy for hepatocellular carcinoma by inhibiting the insulin-like growth factor pathwaymRNA profiling reveals determinants of trastuzumab efficiency in HER2-positive breast cancerSrc mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma modelsAnti-proliferative effect of cytohesin inhibition in gefitinib-resistant lung cancer cellsSmall is beautiful: insulin-like growth factors and their role in growth, development, and cancerHER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature reviewSimultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody.Where now for anti-EGF receptor therapies in colorectal cancer?Amplification of HER2 is a marker for global genomic instability.The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer.Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotiniReversal of oncogene transformation and suppression of tumor growth by the novel IGF1R kinase inhibitor A-928605.In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells.Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours.Artemin, a member of the glial cell line-derived neurotrophic factor family of ligands, is HER2-regulated and mediates acquired trastuzumab resistance by promoting cancer stem cell-like behavior in mammary carcinoma cells.Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimensTrastuzumab emtansine: mechanisms of action and drug resistancePhotodynamic Therapy with Hypericin Improved by Targeting HSP90 Associated Proteins.
P2860
Q24309891-E64B4858-99A3-47E3-A4EE-428D0C0D5548Q24609058-26C98486-A531-48EA-8C46-3E84F434842DQ24633750-483F2405-0479-444D-86B7-D99AF294755CQ24681561-F8E4B0D5-5A77-4F97-A0CF-13B66653BC79Q24795614-38C2C9FC-739D-4EDF-BED7-03408547B220Q24796824-A4D896D0-500B-41A4-96B0-21DCA177CF3CQ24802985-3AF85670-4BB7-43D7-80F2-263811D7CE55Q24803648-E66B9A6E-C5BE-42BF-99D5-D9E4318A3AE2Q24810622-86C04FE1-78C9-4757-8FDE-1BBBE519E5A1Q26772969-D3938961-5BB2-43B3-8CE4-0218536B3E2AQ26777681-6CBC8EB0-CE9A-498D-B9EC-5F1D4E17611DQ26864668-3DF9860D-3959-4705-931E-5E6D106E4FFDQ27004161-35DCDACB-8755-47B9-9FEC-61E9BFEEE852Q27013945-643CDDB1-9228-49E4-BF8D-3966B450F77EQ27025863-A5DA970E-5F18-41E7-A767-8DAAF13EF903Q27025966-3F039994-6EC3-461F-A9E4-5022DEFF7D4BQ27027778-E00F90C4-0DE1-4B82-890F-3A96C3AF8443Q27346475-EA93C0DA-6814-45B7-8B6E-DD4410B30F3BQ27650906-22E63991-103B-4E53-BDF1-7F64B3F5DCE2Q27824857-FD65BF5D-5DBD-4EA2-8890-1F84160BAFE9Q27851628-C70CBE1E-18EF-434D-B328-333B53B40250Q28072513-9E692D12-A031-4DF0-807B-C23F48FCDDD2Q28534009-CD7A9B9B-D9A4-4DA6-81C3-2E4EB32CD6E1Q28543647-9E479F09-8823-4157-AF26-2110C2A7E578Q28544422-2F283F6C-B419-44F8-A4F3-BA9C00B4F907Q28729071-06C0E95E-CD28-48D3-AAA9-1E283F8359ACQ30395770-EC7D393B-4B83-44B8-A2D3-0C30D32C554DQ30932448-F6539C3B-8113-4049-BA52-57914A12E7EEQ31016741-E4481B80-5A59-4D53-85D0-5DDBC66BECF8Q31038305-62A0FE3A-54BB-4705-A41B-398C800207E5Q33375856-97D8006C-65B5-4AC9-AAC9-88C49D5AA200Q33409083-84AD0BC0-E569-4C4D-8245-B4053ACDDF0EQ33416585-E3C9AF76-AB67-4937-BFB3-5BF833165279Q33500359-3C333A41-BA12-4079-9918-BF7D9583D823Q33599144-88917F16-B687-4361-8E4B-ACDA5624DC5FQ33658544-7860671E-527E-4617-9F55-77AC0A7E5408Q33718457-94CCE401-B71E-4647-ACFC-90A39ED7A6E5Q33735413-84931FE7-A9DB-4CF6-A5F0-FB9ABA4A2A84Q33759627-84A60E31-59D2-42A0-81BA-F76DD234DF69Q33765280-62E7CB0D-50E8-41ED-9519-89092300BDF1
P2860
Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Insulin-like growth factor-I r ...... ce to trastuzumab (Herceptin).
@en
Insulin-like growth factor-I receptor signaling and resistance to trastuzumab
@nl
type
label
Insulin-like growth factor-I r ...... ce to trastuzumab (Herceptin).
@en
Insulin-like growth factor-I receptor signaling and resistance to trastuzumab
@nl
prefLabel
Insulin-like growth factor-I r ...... ce to trastuzumab (Herceptin).
@en
Insulin-like growth factor-I receptor signaling and resistance to trastuzumab
@nl
P2093
P2860
P356
P1476
Insulin-like growth factor-I r ...... ce to trastuzumab (Herceptin).
@en
P2093
P2860
P304
P356
10.1093/JNCI/93.24.1852
P407
P577
2001-12-01T00:00:00Z